BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 104 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $336,000 | -37.8% | 20,645 | -39.6% | 0.02% | -51.9% |
Q2 2021 | $540,000 | +382.1% | 34,159 | +44.9% | 0.05% | +300.0% |
Q2 2020 | $112,000 | -58.4% | 23,568 | -69.7% | 0.01% | -50.0% |
Q4 2019 | $269,000 | +460.4% | 77,838 | +361.7% | 0.03% | +550.0% |
Q3 2019 | $48,000 | -11.1% | 16,860 | +48.2% | 0.00% | +33.3% |
Q1 2018 | $54,000 | – | 11,374 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |